Brief: BioNTech Starts Phase 3 Trial of Pumitamig Plus Gilead's Trodelvy for Breast Cancer
Today 11:49
BRIEF-BioNTech Starts Phase 3 Trial of Pumitamig Plus Gilead's Trodelvy for Breast Cancer Oct 22 (Reuters) - BIONTECH SE 22UAy.DE:
ADVANCES PHASE 3 CLINICAL TRIAL OF PUMITAMIG IN COMBINATION WITH GILEAD’S TROP2-DIRECTED ADC SACITUZUMAB GOVITECAN IN TRIPLE-NEGATIVE BREAST CANCER
CO AND GILEAD TO EVALUATE PUMITAMIG WITH SACITUZUMAB GOVITECAN IN FIRST-LINE TNBC
ROSETTA BREAST-01 PHASE 3 TRIAL EVALUATES PUMITAMIG IN TRIPLE-NEGATIVE BREAST CANCER
UNDER TERMS OF AGREEMENT, BIONTECH WILL CONTINUE TO SPONSOR AND LEAD ROSETTA BREAST-01 TRIAL
GILEAD WILL SUPPLY SACITUZUMAB GOVITECAN FOR COMBINATION TRIAL
Source text: ID:nGNX5xXbyM
Further company coverage: [22UAy.DE]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on BioNTech SE
See all newsBioNTech, Gilead to test drug combination in advanced breast cancer trial
Brief: BioNTech Starts Phase 3 Trial of Pumitamig Plus Gilead's Trodelvy for Breast Cancer
Brief: Biontech To Showcase Oncology Late-Stage Pipeline Progress At ESMO 2026
BioNTech's mRNA cancer therapy misses first goal in head and neck trial (updated)
BioNTech's mRNA cancer therapy misses first goal in head and neck trial